Skip to main content

Table 5 Incident rates and median time for T2DM diagnosis at different follow-up times, according to hypertension and CVD diagnosis

From: Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink

   Statin use
   Yes No
Follow up time (years) PS [5-95%] (N = 1,448,993) Hazard ratio (95% CI)* Incident T2DM per 1000 person-years (95% CI) Nº T2DM /Median time (days) Incident T2DM per 1000 person-years (95% CI) Nº T2DM /Median time (days)
Total sample
0-1 yr 1.52 (1.47-1.57) 19.97 (19.52-20.42) 7,634/139 11.53 (11.33-11.74) 12,189/210
1-3 yr 1.22 (1.19-1.25) 20.11 (19.78-20.44) 13,786/727 13.35 (13.34-13.37) 21,418/644
3-5 yr 1.73 (1.68-1.80) 24.56 (24.12-25.00) 11,858/1,440 11.61 (11.38-11.84) 9,773/1,394
5-10 yr 2.25 (2.17-2.34) 30.03 (29.55-30.53) 14,523/2,450 10.85 (10.59-11.12) 6,534/2,312
10-15 yr 3.05 (2.71-3.43) 34.93 (33.53-36.39) 2,292/4,174 10.20 (9.38-11.10) 543/4,166
15-20 yr 3.63 (2.44-5.38) 42.24 (36.90-48.36) 210/5,877 12.24 (9.10-16.51) 43/5,773
20-25 yr n.e. 13.10 (1.84-93.00) 1/ - 0 0/ -
No hypertension
0-1 yr 2.05 (1.96-2.15) 19.53 (18.97-20.11) 4,486/134 8.65 (8.44-8.85) 6,893/215
1-3 yr 1.50 (1.45-1.55) 18.64 (18.23-19.06) 7,694/727 10.60 (10.42-10.77) 13,114/653
3-5 yr 2.00 (1.92-2.09) 22.15 (21.61-22.69) 6,463/1,439 9.56 (9.33-9.80) 6,550/1,400
5-10 yr 2.50 (2.39-2.61) 27.65 (27.06-28.24) 8,502/2,482 9.32 (9.06-9.59) 4,750/2,335
10-15 yr 3.14 (2.75-3.58) 32.86 (31.26-34.55) 1,541/4,180 9.31 (8.48-10.21) 446/4,186
15-20 yr 3.84 (2.52-5.86) 41.61 (35.64-48.59) 160/5,877 11.55 (8.41-15.88) 38/5,780
20-25 yr n.e. 0 0/ - 0 0/ -
Hypertension
0-1 yr 0.96 (0.91-1.01) 20.62 (19.91-21.35) 3,148/145 20.40 (19.86-20.96) 5,296/204
1-3 yr 0.84 (0.81-0.88) 22.33 (21.77-22.89) 6,092/726 24.20 (23.68-24.72) 8,304/625
3-5 yr 1.22 (1.15-1.29) 28.24 (27.50-29.00) 5,395/1,442 20.51 (19.82-21.23) 3,223/1,380
5-10 yr 1.56 (1.46-1.67) 34.22 (33.37-35.10) 6,021/2,405 19.25 (18.38-20.17) 1,784/2,264
10-15 yr 2.19 (1.68-2.84) 40.09 (37.32-43.06) 751/4,156 18.33 (15.02-22.37) 97/4,073
15-20 yr 2.32 (0.77-7.01) 44.38 (33.64-58.56) 50/5,876 22.38 (9.31-53.77) 5/ -
20-25 yr n.e. 0 0/ - 0 0/ -
No CVD
0-1 yr 1.74 (1.67-1.80) 20.72 (20.22-21.24) 6,260/136 10.74 (10.54-10.95) 10,474/213
1-3 yr 1.31 (1.28-1.35) 20.37 (19.99-20.75) 11,037/725 12.93 (12.75-13.11) 19,254/647
3-5 yr 1.85 (1.78-1.92) 24.94 (24.44-25.45) 9,325/1,438 11.18 (10.95-11.42) 9,022/1,393
5-10 yr 2.34 (2.24-2.43) 30.44 (29.86-31.02) 10,512/2,416 10.56 (10.30-10.83) 6,134/2,317
10-15 yr 2.96 (2.61-3.35) 33.58 (31.85-35.97) 1,379/4,151 10.08 (9.26-10.99) 523/4,166
15-20 yr 3.76 (2.49-5.67) 41.78 (35.54-49.11) 147/5,985 11.81 (8.70-16.04) 41/5,773
20-25 yr n.e. 0 0/ - 0 0/ -
CVD
0-1 yr 0.75 (0.69-0.82) 17.11 (16.23-18.04) 1,374/147 21.05 (20.08-22.07) 1,715/196
1-3 yr 0.75 (0.70-0.80) 19.12 (18.42-19.85) 2,749/733 23.77 (22.79-24.79) 2,164/613
3-5 yr 0.97 (0.88-1.06) 23.24 (22.35-24.17) 2,533/1,445 21.30 (19.83-22.88) 751/1,408
5-10 yr 1.34 (1.19-1.50) 29.05 (28.16-29.96) 4,011/2,540 18.73 (16.98-20.66) 400/2,223
10-15 yr 2.26 (1.42-3.57) 37.19 (34.85-39.68) 913/4,224 14.70 (9.49-22.79) 20/4,204
15-20 yr 1.45 (0.31-6.74) 43.36 (33.87-55.08) 63/5,762 48.47 (12.12-193.81) 2/ -
20-25 yr n.e. 0 0/ - 0 0/ -
  1. PS – propensity score; *Final model: adjusted for age and propensity score; n.e. – no estimation.